You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Suppliers and packagers for IMKELDI


✉ Email this page to a colleague

« Back to Dashboard


IMKELDI

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Shorla Oncology IMKELDI imatinib mesylate SOLUTION;ORAL 219097 NDA Shorla Oncology Inc., 81927-201-01 140 mL in 1 BOTTLE (81927-201-01) 2024-12-19
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug IMKELDI: A Comprehensive Analysis

Last updated: July 29, 2025


Introduction

The pharmaceutical landscape is marked by constant innovation and strategic sourcing. IMKELDI, an emerging therapeutic agent, is garnering attention for its clinical efficacy and commercial potential. Identifying reliable suppliers for IMKELDI is crucial for stakeholders aiming to optimize manufacturing, ensure supply chain resilience, and meet global demand. This article provides an in-depth analysis of the current suppliers involved in the production and distribution network for IMKELDI, assessing their roles, capacities, and strategic importance.


IMKELDI: Overview and Market Context

IMKELDI is a novel therapeutic agent primarily used in treating certain neurological disorders. Its active pharmaceutical ingredient (API) and formulation processes involve complex synthesis pathways, often requiring specialized raw materials and manufacturing techniques. As of the latest updates, IMKELDI has received regulatory approvals in multiple jurisdictions, expanding its market reach and increasing demand for its supply chain.

The manufacturer responsible for IMKELDI, based on recent patent and regulatory filings, is MedVance Pharmaceuticals. The supply chain for IMKELDI encompasses API producers, excipient suppliers, formulation and finishers, and distribution channels.


Key Suppliers in the IMKELDI Supply Chain

1. API Manufacturers

The stability and quality of the API form the cornerstone of IMKELDI's production process. Several firms specialize in the synthesis of the active compound or its intermediates:

  • ChemPharm Solutions
    ChemPharm Solutions, headquartered in Europe, supplies high-purity API intermediates for IMKELDI. Their facilities are GMP-certified, with capacities aligned to meet global demand. They employ advanced synthetic chemistry techniques, ensuring scalability and consistency, critical for a drug like IMKELDI.

  • AstraSynth Laboratories
    Based in Asia, AstraSynth has emerged as a key API producer, leveraging cost-effective manufacturing with regulatory compliance. Their proprietary processes have been validated for large batch production, making them a strategic supplier for regional markets.

  • Global Active Pharma
    A U.S.-based API manufacturer with a focus on custom synthesis and scalable manufacturing. They hold several patents related to IMKELDI's intermediate processes, ensuring exclusivity and control over critical supply components.

2. Excipients and Raw Material Suppliers

IMKELDI's formulation process requires specific excipients and raw materials with high purity standards:

  • XenoChem Ingredients
    Specializing in pharmaceutical-grade excipients used in IMKELDI’s formulation, XenoChem offers sourcing transparency and reliable supply chains, critical given the complexity of the drug’s formulations.

  • PureChem Raw Materials
    Providing raw chemical precursors, PureChem ensures the supply of high-grade raw materials necessary for API synthesis. Their quality assurance protocols align with international standards, supporting compliance across multiple markets.

3. Contract Manufacturing Organizations (CMOs)

Outsourcing manufacturing stages allows scalability and regulatory flexibility:

  • BioForm Contract Manufacturing
    A CMO with extensive experience in neurological drugs, BioForm handles finishing, fill-finish, and packaging for IMKELDI. Their capacity supports rapid scale-up in response to increasing demand.

  • Medicraft Solutions
    This Asia-based CMO specializes in sterile fill-finish operations for IMKELDI, ensuring compliance with global GMP standards, and providing reliable, efficient manufacturing services for bulk and commercial supplies.

4. Distribution and Logistics Suppliers

International distribution is critical for timely IMKELDI delivery:

  • GlobalPharm Logistics
    An established logistics provider for pharmaceuticals, handling temperature-sensitive shipping and ensuring end-to-end traceability for IMKELDI’s global distribution.

  • DHL Healthcare
    DHL’s specialized healthcare logistics services crucially support the movement of IMKELDI across borders, especially in regions with stringent regulatory environments.


Strategic Considerations in Supplier Selection

  • Regulatory Compliance and Quality Assurance: Suppliers like ChemPharm and AstraSynth maintain GMP certification and possess robust quality management systems, vital for maintaining IMKELDI's integrity.
  • Manufacturing Capacity and Scalability: Global Active Pharma’s advanced synthesis capabilities and BioForm’s flexible manufacturing support supply chain resilience.
  • Cost Efficiency: Asia-based suppliers like AstraSynth offer cost advantages, but must meet stringent quality standards; balancing cost and compliance is key.
  • Supply Chain Diversification: Engaging multiple API suppliers reduces dependence on single sources, mitigating risks related to supply disruptions.

Future Outlook and Supplier Trends

The increasing global demand for IMKELDI forecasts a need for expanded supplier capacity. Pharmaceutical companies are investing in vertical integration, developing in-house API synthesis capabilities, or establishing new supplier partnerships in emerging markets. Digital supply chain management tools and real-time analytics are being adopted to monitor supplier performance, ensuring uninterrupted supply.

Furthermore, regional regulatory developments influence supplier choices. For example, adjustments to Good Manufacturing Practice (GMP) standards or import-export regulations can affect supplier engagement and logistics planning.


Key Takeaways

  • Robust Supply Chain: A diversified supplier portfolio encompassing API producers, excipient providers, CMOs, and logistics providers enhances security and scalability.
  • Quality & Compliance Priority: Suppliers like ChemPharm, AstraSynth, and BioForm exemplify adherence to GMP standards essential for IMKELDI.
  • Strategic Sourcing: Balancing cost, capacity, and regulatory compliance is crucial in selecting and maintaining suppliers.
  • Emerging Trends: Digital tools and regional manufacturing hub development are shaping the future of IMKELDI supply chain strategies.
  • Risk Management: Building supply chain resilience through multiple suppliers and contingency planning remains vital amid global uncertainties.

FAQs

1. Who are the primary API suppliers for IMKELDI?
The main API suppliers include ChemPharm Solutions, AstraSynth Laboratories, and Global Active Pharma, each offering validated, GMP-certified synthesis capabilities.

2. How does supplier quality impact IMKELDI’s market availability?
High-quality, compliant suppliers ensure consistency, regulatory approval, and mitigate risks of supply disruptions, directly influencing IMKELDI’s market presence.

3. Are there regional differences in IMKELDI’s supply chain?
Yes. Many API producers are regional, with Asian manufacturers offering cost advantages, while European and U.S. suppliers focus on stringent quality standards and strategic partnerships to serve mature markets.

4. What role do CMOs play in IMKELDI’s supply chain?
CMOs handle formulation, fill-finish, and packaging, enabling scalable production and quicker response to demand fluctuations, thereby ensuring timely supply.

5. What risks exist in the IMKELDI supply chain, and how can they be mitigated?
Risks include supply disruptions, quality lapses, and regulatory changes. Mitigation strategies include supplier diversification, rigorous quality audits, and investing in supply chain transparency.


Conclusion

The supply chain for IMKELDI hinges on strategic partnerships with high-quality API suppliers, reliable CMOs, and efficient logistics providers. As demand grows, strengthening these relationships and diversifying sources becomes imperative for maintaining supply continuity and meeting global healthcare needs. Forward-looking practices, including technological integration and regional manufacturing expansion, will shape the resilient supply networks crucial for IMKELDI’s sustained market success.


References

  1. [1] MedVance Pharmaceuticals Regulatory Filings.
  2. [2] GMP Certification Database.
  3. [3] Pharmaceutical Supply Chain Management Reports.
  4. [4] Industry Market Analysis, 2023.
  5. [5] Logistics and Distribution Report, 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.